Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

KBioBox Offers Improved GUIDE-Seq Analysis Pipeline for CRISPR Experiments.
  • USA - English


News provided by

KBioBox LLC

Aug 22, 2017, 03:00 ET

Share this article

Share toX

Share this article

Share toX

KBioBox Genetic BioInformatics Data Analysis
KBioBox Genetic BioInformatics Data Analysis

Worcester. MA (PRWEB) August 22, 2017 -- KBioBox is pleased to announce the creation of a new service pipeline built upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox has adapted their core technology and direct alignment algorithms to extend the open source GUIDE-Seq computation pipeline to be provide scientists with easy to understand reports, extended indel analysis, and translocation analysis.

"KBioBox technology ensures sophisticated testing

Post this

“The extended GUIDE-Seq analysis is an exciting extension of the "off the shelf" bio-informatic GUIDE-seq pipeline, providing additional critical information to scientists examining the results of a gene editing experiment, particularly in the areas of CRISPR based therapeutics,” enthused Kryngle Daly CEO of KBioBox LLC. In addition to the basic GUIDE-seq output, KBioBox offers analysis and reporting of Cas9 cleavage site fidelity, extended indel analysis (including large indels), and potential translocation analysis. KBioBox’s extended GUIDE-Seq analysis can also be customized to include additional genomes in experimental systems such as viral reservoirs.
https://www.kbiobox.com/checkedit

The power of KBioBox’s patented genomic search engine is in its simplicity, accuracy, and speed, processing full genome searches in minutes. The simplicity of the engine affords customization to any genomic analysis application, from novel uses within gene editing and whole genome sequence to canonical uses such as alignment and variant analysis. The customized extension of GUIDE-Seq to provide clients with the precise data they require is a typical example of this flexibility.Other applications include urgent screening of sequencing results for mutations that could lead to diseases or cancers, or as complicated as multi species alignment and comparison.

About KBioBox llc

KBioBox LLC is a bioinformatics technology company which provides accurate and fast genomics analysis services, including CRISPR Off Target Analysis, Gene Editing Design, post-edit analysis, and other services. At the core of KBioBox technology is a proprietorial, patented search algorithm that can search and align genomic data with speed and accuracy. KBioBox has helped both academic and industry partners in various off target analysis, genomic analysis, and gene edit design projects that have allowed researchers to overcome specific experimental barriers, design better tools for their research, and better analyze their results. Current developed KBioBox applications include Off Target Analysis (OTA) for CRISPRs and TALENs, BioDesign for CRISPR guide RNA’s, VCF analysis, alignment and indel analysis, translocation analysis, and other custom applications. The technology is attractive to pharmaceutical development companies, next generation sequencing users, and the academic universe both in the USA and internationally. (info(at)kbiobox(dot)com Tel: 508 762 9219 )

KBioBox offers intuitive, easy to use, Online Tools

KBioBox Gene Edit Tool

Advances in gene editing technology, in particular the CRISPR/Cas9 system, have revolutionized gene editing with promise for advances in basic science, biotechnology, and biomedical research. With the simplicity of modern gene editing technologies come problematic off target interactions which can lead to failed experiments or cell death. KBioBox's Gene Edit Off Target Analysis Tool was built to predict potential off targets, allowing scientists to redesign a target, or "know where to look" after a gene edit has been affected. Able to search entire genomes in under a minute, and customizable to any chemistry or enzyme protocol, KBioBox’s CRISPR off target analysis algorithm predicts nearly 97% of off targets identified by GUIDE-Seq (currently the industry standard in whole genome off target reporting) compared to less than 50% by eCRISP and MIT’s CRISPR design tool. Our Gene Edit Off Target Analysis Tool can provide a level of quality assurance previously unavailable for gene edits.
Scientists are invited to run one complimentary analysis.

Access Gene Edit Off Target Analysis Tool. http://www.kbiobox.com/offtarget

KBioBox Gene Edit Design Tool

The simplicity of modern gene editing technology, in particular the CRISPR/Cas9 chemistry, has afforded advances in many areas of science and medicine. The cost of this simplicity is the challenge to determine strong binding targets with minimal or no off targets, a task that can prove challenging for any scientist. KBioBox's Gene Edit Design Tool handles the tedious aspects required to design a strong gene edit. For a desired edit, the Gene Edit Design tool considers all potential targets in a region and ranks them based on off target potential and severity of "hits", returning the "top ten" best designs in under a minute. With each design comes with a full genome an off target analysis report, providing scientists with confidence to make the best decision.

Access The Gene Edit Design Tool. https://www.kbiobox.com/biodesign.

Kryngle Daly, KBioBox LLC, http://www.kbiobox.com, +1 508 762 9219, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.